[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349510-105":59,"doc-detail-349510-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ube2a-as-a-prognostic-indicator-across-human-cancers-insights-from-multi-omics-and-immune-landscape-analyses","UBE2A as a prognostic indicator across human cancers - Insights from multi-omics and immune landscape analyses","","Ubiquitin-conjugating enzyme E2A (UBE2A) has been linked to tumor development, yet its pan-cancer relevance remains insufficiently defined. This study integrates public multi-omics datasets, including TCGA, GEO, and GTEx, to characterize UBE2A expression, clinical associations, immune relevance, molecular features, and downstream biological functions across cancer types. Analyses include immune infiltration correlations and functional enrichment, supporting UBE2A as an adverse prognostic biomarker.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ube2a-as-a-prognostic-indicator-across-human-cancers-insights-from-multi-omics-and-immune-landscape-analyses/349510/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ube2a-as-a-prognostic-indicator-across-human-cancers-insights-from-multi-omics-and-immune-landscape-analyses/349510.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of the study on UBE2A?","Question",{"text":112,"@type":113},"To systematically define UBE2A expression patterns and determine its prognostic and immune-related significance across multiple human cancer types.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which datasets were used to evaluate UBE2A in a pan-cancer context?",{"text":117,"@type":113},"The study integrated public datasets, including The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Genotype-Tissue Expression (GTEx).",{"name":119,"@type":110,"acceptedAnswer":120},"How was UBE2A functionally validated in the study?",{"text":121,"@type":113},"UBE2A knockdown was performed in breast cancer cell lines, and the results showed suppressed proliferation, migration, and invasion.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349510,1790869746,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","MOLECULAR MEDICINE REPORTS 34: 260, 2026  \nUBE2A as a prognostic indicator across human cancers: Insights from multi‑omics and immune landscape analyses  \nYUN WEN 1 and PENGFEI LUO2  \n1  \nDepartment of Breast and Thyroid Surgery, The Central Hospital of Yongzhou, Yongzhou, Hunan 425000, P.R. China; 2  \nDepartment of Oncology, The Central Hospital of Yongzhou, Yongzhou, Hunan 425000, P.R. China  \nReceived March 26, 2026; Accepted June 25, 2026  \nDOI: 10. 3892/mmr.2026.13970  \nAbstract. Ubiquitin‑conjugating enzyme E2A (UBE2A), a member of the ubiquitin‑conjugating E2 enzyme family, has been implicated in tumor development; however, its role across human cancer types remains incompletely understood. The present study aimed to systematically characterize the expres‑ sion pattern, prognostic importance and immune relevance of UBE2A in a pan‑cancer context. Public datasets, including The Cancer Genome Atlas, Gene Expression Omnibus and Genotype‑Tissue Expression, were integrated to evaluate UBE2A expression, clinical importance, molecular charac‑ teristics, immune associations and biological functions across cancer types. Single‑cell RNA sequencing data were analyzed  \nCorrespondence to: Dr Pengfei Luo, Department of Oncology, The Central Hospital of Yongzhou, 396 Yiyun Road, Lengshuitang, Yongzhou, Hunan 425000, P.R. China  \nE‑mail: [lpf1981@yeah.net](lpf1981@yeah.net)  \nAbbreviations: UBE2A, ubiquitin conjugating enzyme E2A; TCGA, The Cancer Genome Atlas; GTEx, Genotype‑Tissue Expression Project; ROC, receiver operating characteristic; AUC, area under the curve; OS, overall survival; DFS, disease‑free survival; DMFS, distant metastasis‑free survival; RFS, relapse‑free survival; GSEA, Gene Set Enrichment Analysis; KEGG, Kyoto Encyclopedia Of Genes And Genomes; GO, Gene Ontology; TMB, tumor mutational burden; MSI, microsatellite instability analysis; CCK‑8; Cell Counting Kit‑8; BLCA, bladder urothelial carcinoma; CESC, cervical squamous cell carcinoma; CHOL, cholangiocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head‑neck squamous cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; STAD, stomach adenocarcinoma; gastric adenocarcinoma; THCA, thyroid carcinoma; COAD, colon adenocarcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; PRAD, prostate adenocarcinoma; STES, stomach and esophageal carcinoma; ESAD, esophageal adenocarcinoma; UVM, uveal melanoma; SARC, sarcoma; THYM, thymoma; TISCH2, Tumor Immune Single Cell Hub 2  \nKey words: ubiquitin‑conjugating enzyme E2, pan‑cancer, prognosis, immune infiltration, breast cancer, biomarker  \nto investigate the cellular distribution of UBE2A. Functional validation was performed through UBE2A knockdown in breast cancer cell lines. Results indicated that UBE2A was significantly upregulated in a number of cancer types and was associated with unfavorable overall and progression‑free survival. UBE2A expression exhibited significant correlations with immune cell infiltration and immune checkpoint‑associ‑ ated genes across cancer types. Functional enrichment analyses indicated that UBE2A was primarily involved in cell cycle regulation and proliferative processes. Single‑cell analysis revealed preferential UBE2A expression in proliferative T‑cell populations. Furthermore, in vitro experiments demonstrated thatUBE2A knockdown significantly suppressed breast cancer cell proliferation, migration and invasion. Overall, UBE2A was shown to be a promising prognostic biomarker associated with tumor progression, cell cycle activity and immune‑associated characteristics across cancer types. Its preferential expression in proliferative T‑cell populations and oncogenic role in breast cancer suggest that UBE2A may serve as a potential thera‑ peutic target and a candidate biomarker for evaluating tumor prognosis and the tumor immune microenvironment.  ","cbCaiaWjVeuJ2zJF","https://ap.wps.com/l/cbCaiaWjVeuJ2zJF","pdf",23491232,23,"English","# Abstract\n# Introduction\n## Cancer burden and heterogeneity\n## Therapeutic advances and remaining challenges\n## Pan-cancer analytical frameworks","[{\"question\":\"What was the main goal of the study on UBE2A?\",\"answer\":\"To systematically define UBE2A expression patterns and determine its prognostic and immune-related significance across multiple human cancer types.\"},{\"question\":\"Which datasets were used to evaluate UBE2A in a pan-cancer context?\",\"answer\":\"The study integrated public datasets, including The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Genotype-Tissue Expression (GTEx).\"},{\"question\":\"How was UBE2A functionally validated in the study?\",\"answer\":\"UBE2A knockdown was performed in breast cancer cell lines, and the results showed suppressed proliferation, migration, and invasion.\"}]","UBE2A as a prognostic indicator across human cancers - Insights from multi-omics and immune landscape analyses | PDF",1790084015,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/deb31f334adfb9c51290c48f3c4156ed.webp",983,1357,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42b78bc640d82a2c0a73b5b34c89d21a.webp",982,1356,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a30ca63fa5071fd321b0f7b7791f3e0b.webp",981,1354,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5e537c1500f3a649fb41da19b3b1d87.webp",980,1353]